Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968551 | 0.87 | ALDH1A1 (0.41) | ALOX15ALOX12LMNASMN1; SMN2HTT | |
| SCHEMBL4968603 | 0.84 | MEN1 (0.32) | NPC1RAB9AALOX15ALOX12LMNA | |
| SCHEMBL4970612 | 0.84 | MEN1 (0.32) | NPC1RAB9AALOX15ALOX12LMNA | |
| SCHEMBL4968013 | 0.79 | GABRA1 (0.34) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4969590 | 0.72 | GPR35 (0.38) | RAB9AALOX12LMNAL3MBTL1HTT | |
| SCHEMBL4969584 | 0.72 | GPR35 (0.38) | RAB9AALOX12LMNAL3MBTL1HTT | |
| SCHEMBL4968980 | 0.70 | ALDH1A1 (0.39) | ALOX15ALOX12LMNASMN1; SMN2HTT | |
| SCHEMBL4970133 | 0.70 | ALDH1A1 (0.39) | ALOX15ALOX12LMNASMN1; SMN2HTT | |
| SCHEMBL4968591 | 0.68 | HTT (0.39) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL4970600 | 0.68 | HTT (0.39) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | NPC1 818/4885RAB9A 3322/4885ALOX15 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.